ResMed Inc. (RMD) Price Target Raised to $74.00

ResMed Inc. (NYSE:RMD) had its target price boosted by stock analysts at BMO Capital Markets from $70.00 to $74.00 in a note issued to investors on Friday, October 27th. The firm currently has a “market perform” rating on the medical equipment provider’s stock. BMO Capital Markets’ price objective would suggest a potential downside of 11.90% from the stock’s current price.

RMD has been the topic of a number of other research reports. Zacks Investment Research cut ResMed from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a report on Friday, October 27th. Barclays PLC boosted their target price on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Friday, October 27th. Credit Suisse Group AG lowered ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Bank of America Corporation lowered ResMed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $67.57.

Shares of ResMed (RMD) traded up $0.94 during trading on Friday, hitting $84.00. The stock had a trading volume of 918,200 shares, compared to its average volume of 873,090. ResMed has a one year low of $57.45 and a one year high of $87.81. The company has a market cap of $11,786.54, a PE ratio of 28.94, a P/E/G ratio of 1.85 and a beta of 0.79. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the prior year, the business posted $0.62 EPS. The business’s revenue was up 12.5% compared to the same quarter last year. analysts forecast that ResMed will post 3 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://weekherald.com/2017/11/14/resmed-inc-rmd-price-target-raised-to-74-00.html.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total value of $105,625.00. Following the completion of the transaction, the chief financial officer now directly owns 71,772 shares in the company, valued at $6,064,734. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $76.74, for a total value of $1,534,800.00. Following the transaction, the director now owns 314,800 shares of the company’s stock, valued at $24,157,752. The disclosure for this sale can be found here. Insiders sold 201,234 shares of company stock valued at $16,339,637 over the last quarter. Corporate insiders own 1.77% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. YorkBridge Wealth Partners LLC raised its position in shares of ResMed by 4.9% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after acquiring an additional 69 shares during the last quarter. Creative Planning raised its position in shares of ResMed by 97.1% during the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after acquiring an additional 823 shares during the last quarter. Toronto Dominion Bank raised its position in shares of ResMed by 12.8% during the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after acquiring an additional 197 shares during the last quarter. Huntington National Bank bought a new position in shares of ResMed during the second quarter worth about $156,000. Finally, Nomura Holdings Inc. acquired a new stake in ResMed during the first quarter worth approximately $201,000. Institutional investors own 58.86% of the company’s stock.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply